Topic
Topic
A rare case report documents psoriasis and vitiligo in one patient, exposing opposing immune pathways in the same skin — and a counseling and monitoring problem for clinicians.
Research links dupilumab to new-onset vitiligo and points to early recognition, a nemolizumab switch, and targeted topical therap…
The FDA has cleared the IND for a Phase 2 study of EB06 in vitiligo, advancing the investigational candidate into mid-stage testi…
An October 2026 JID supplement entry by Tang et al. reports that the plant-derived saponin Ecliptasaponin A ameliorated vitiligo-…
CXCL10 correlates with clinical response to ruxolitinib cream in vitiligo, per the Phase 2 TRuE-V mechanism-of-action study publi…
Dermatology Times examines how clinicians should choose between topical and oral JAK inhibitors for vitiligo as systemic options…
Clinicians are splitting vitiligo management by age group, weighing therapy choice, timing and repigmentation goals differently i…
Dermatology Times clinicians compare vitiligo treatment strategies across age groups, weighing topical, light-based and systemic…
Fall Clinical Derm 2026 experts say JAK inhibitors should move earlier in AD and vitiligo care, before disease becomes chronic an…
Ritlecitinib 100 mg drove a 21.86% F-VASI75 response at week 52 in the phase 3 TRANQUILLO 2 trial of nonsegmental vitiligo, again…
